Financing was co-led by Forbion and General Atlantic, with participants including RA Capital Management, OrbiMed, and Lilly Asia Ventures.

GP leaders across the country are advising practices to push back on private providers requesting input for weight-loss jab ...

The GLP-1s include semaglutide (Ozempic, Wegovy) and the combination of GLP-1/GIP drug tirzepatide (Mounjaro, Zepbound).

Distracted eating, as it is termed in scientific literature, coincides with greater flexibility in where we can eat our food and the accessibility of distractions. As a result, “you get this weird ...

As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two main factors: human resources and finance. On one side, there's the potential ...

Highmark Health President and CEO David Holmberg discussed the uncertainties facing the insurance industry, including the ...

A UK biotechnology startup is entering the crowded obesity drug market, armed with $411 million and a promising ...

Read the article below to know if Jonathan Van Ness is taking a weight loss medication as he makes a revelation about his ...

Jonathan Van Ness is seen on the Netflix show, Queer Eye. He has, for the first time, spoken publicly about using weight loss ...

Washington State Labor & Industries is refusing to pay a Kitsap County woman’s medical bills after she suffered injuries from ...

Eli Lilly’s obesity drug Zepbound is now covered by Medicare for sleep apnea treatment, expanding access to the costly ...

"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...